(UroToday.com) In the Proffered Paper Session of the European Society for Medical Oncology (ESMO) Annual Congress focusing on prostate cancer, Dr. Neeraj Agarwal presented results of the COSMIC-021 cohort 6, examining the role of cabozantinib and atezolizumab in patients with metastatic castration-resistant prostate cancer (mCRPC).